JP2018536390A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536390A5 JP2018536390A5 JP2018517357A JP2018517357A JP2018536390A5 JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5 JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018517357 A JP2018517357 A JP 2018517357A JP 2018536390 A5 JP2018536390 A5 JP 2018536390A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- eukaryotic cell
- seq
- trc1
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 82
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 40
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 238000003776 cleavage reaction Methods 0.000 claims description 15
- 230000007017 scission Effects 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 11
- 239000013607 AAV vector Substances 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 241000702421 Dependoparvovirus Species 0.000 claims description 7
- 210000003527 eukaryotic cell Anatomy 0.000 claims 20
- 210000000349 chromosome Anatomy 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 230000006801 homologous recombination Effects 0.000 claims 2
- 238000002744 homologous recombination Methods 0.000 claims 2
- 230000006780 non-homologous end joining Effects 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 description 32
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 19
- 238000010361 transduction Methods 0.000 description 18
- 230000026683 transduction Effects 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 102100021765 E3 ubiquitin-protein ligase RNF139 Human genes 0.000 description 10
- 101001106970 Homo sapiens E3 ubiquitin-protein ligase RNF139 Proteins 0.000 description 10
- 101150058049 car gene Proteins 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 7
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 101000666856 Homo sapiens Vasoactive intestinal polypeptide receptor 1 Proteins 0.000 description 6
- 108010002586 Interleukin-7 Proteins 0.000 description 6
- 102100038388 Vasoactive intestinal polypeptide receptor 1 Human genes 0.000 description 6
- 238000002864 sequence alignment Methods 0.000 description 6
- 230000009469 supplementation Effects 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 101150066002 GFP gene Proteins 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229960004857 mitomycin Drugs 0.000 description 4
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 238000007847 digital PCR Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131109A JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562237382P | 2015-10-05 | 2015-10-05 | |
| US62/237,382 | 2015-10-05 | ||
| US201662297445P | 2016-02-19 | 2016-02-19 | |
| US62/297,445 | 2016-02-19 | ||
| PCT/US2016/055472 WO2017062439A1 (en) | 2015-10-05 | 2016-10-05 | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131109A Division JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536390A JP2018536390A (ja) | 2018-12-13 |
| JP2018536390A5 true JP2018536390A5 (cg-RX-API-DMAC7.html) | 2019-11-14 |
| JP6929837B2 JP6929837B2 (ja) | 2021-09-15 |
Family
ID=57184827
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517357A Active JP6929837B2 (ja) | 2015-10-05 | 2016-10-05 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2021131109A Pending JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A Pending JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A Pending JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131109A Pending JP2022000019A (ja) | 2015-10-05 | 2021-08-11 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2023133416A Pending JP2023175698A (ja) | 2015-10-05 | 2023-08-18 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
| JP2025092415A Pending JP2025143265A (ja) | 2015-10-05 | 2025-06-03 | ヒトｔ細胞受容体アルファ定常領域遺伝子中に見出される認識配列に対して操作されたメガヌクレアーゼ |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10799535B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3940070A1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6929837B2 (cg-RX-API-DMAC7.html) |
| AU (4) | AU2016333886B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3001008A1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK3680329T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2883116T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017062439A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3001008A1 (en) * | 2015-10-05 | 2017-04-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| ES2920525T3 (es) | 2015-10-05 | 2022-08-05 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| AU2017248259A1 (en) * | 2016-04-07 | 2018-10-25 | Bluebird Bio, Inc. | Chimeric antigen receptor T cell compositions |
| AU2017250769B2 (en) * | 2016-04-15 | 2022-07-14 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| WO2019070856A1 (en) * | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS |
| AU2018355587B2 (en) * | 2017-10-27 | 2023-02-02 | The Regents Of The University Of California | Targeted replacement of endogenous T cell receptors |
| CN111918659B (zh) * | 2017-10-30 | 2024-01-30 | 派克特制药公司 | 原代细胞基因编辑 |
| EP3704238B1 (en) * | 2017-11-01 | 2024-01-03 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
| RU2020135720A (ru) | 2018-04-02 | 2022-05-04 | Пэкт Фарма, Инк. | Пептид-мнс compact |
| CA3095795A1 (en) * | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2020106633A1 (en) * | 2018-11-19 | 2020-05-28 | Altius Institute For Biomedical Sciences | Compositions and methods for detection of cleavage of genomic dna by a nuclease |
| EP3921419A4 (en) * | 2019-02-08 | 2023-04-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | SIRT2-ABLATING CHIMERA T-CELLS |
| IL285534B2 (en) | 2019-02-12 | 2025-04-01 | Pact Pharma Inc | Preparations and methods for identifying antigen-specific T cells |
| WO2020205759A1 (en) * | 2019-03-29 | 2020-10-08 | Pact Pharma, Inc. | Personalized neoantigen-specific adoptive cell therapies |
| KR102691932B1 (ko) | 2019-04-03 | 2024-08-06 | 프리시젼 바이오사이언시스 인코포레이티드 | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 |
| WO2020227534A1 (en) | 2019-05-07 | 2020-11-12 | Precision Biosciences, Inc. | Optimization of engineered meganucleases for recognition sequences |
| US20220273715A1 (en) | 2019-07-25 | 2022-09-01 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
| JP2022544825A (ja) | 2019-08-20 | 2022-10-21 | プレシジョン バイオサイエンシズ，インク． | 細胞免疫療法のためのリンパ球枯渇投与レジメン |
| JP2022547072A (ja) * | 2019-09-06 | 2022-11-10 | アヴェクタス リミテッド | エクスビボ細胞療法用途のための免疫細胞の操作 |
| WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| CN114728021B (zh) * | 2019-11-05 | 2025-06-03 | 隆萨沃克斯维尔股份有限公司 | 同种异体t细胞和其产生方法 |
| CA3160096A1 (en) | 2019-12-06 | 2021-06-10 | Bruce J. Mccreedy Jr. | Methods for cancer immunotherapy |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
| US20250127811A1 (en) | 2021-01-28 | 2025-04-24 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| CA3173245A1 (en) * | 2021-04-22 | 2022-10-22 | James Jefferson Smith | Engineered meganucleases that target human mitochondrial genomes |
| WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
| WO2023133525A1 (en) | 2022-01-07 | 2023-07-13 | Precision Biosciences, Inc. | Optimized polynucleotides for protein expression |
| EP4646223A1 (en) | 2023-01-05 | 2025-11-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for the human t cell receptor alpha constant region gene |
| WO2024236547A1 (en) | 2023-05-18 | 2024-11-21 | Inceptor Bio, Llc | Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof |
| WO2025046513A1 (en) | 2023-08-29 | 2025-03-06 | Inceptor Bio, Llc | Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| US20100151556A1 (en) | 2002-03-15 | 2010-06-17 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| US20070036773A1 (en) | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| ATE549401T1 (de) * | 2005-10-18 | 2012-03-15 | Prec Biosciences | Rational konstruierte meganukleasen mit veränderter sequenzspezifität und dna- bindungsaffinität |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| EP2329017A2 (en) | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| EP2331566B1 (en) | 2008-08-26 | 2015-10-07 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| CA2805442C (en) * | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| WO2012167192A2 (en) | 2011-06-01 | 2012-12-06 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| JP6463672B2 (ja) | 2012-05-25 | 2019-02-06 | セレクティスＣｅｌｌｅｃｔｉｓ | Ｔｃｒアルファ欠損ｔ細胞を増殖させるためのプレｔアルファまたはその機能性変種の使用 |
| KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| EP2975942B1 (en) | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| ES2831315T3 (es) | 2013-04-03 | 2021-06-08 | Memorial Sloan Kettering Cancer Center | Generación efectiva de células T dirigidas al tumor derivadas de células madre pluripotentes |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Ｒｎａガイドｃａｓヌクレアーゼ系を用いることによって免疫療法のためにｔ細胞を操作するための方法 |
| US10006052B2 (en) | 2013-05-31 | 2018-06-26 | Cellectis | Laglidadg homing endonuclease cleaving the C-C chemokine receptor type-5 (CCR5) gene and uses thereof |
| CA2913872C (en) | 2013-05-31 | 2022-01-18 | Cellectis | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof |
| AU2014337248B2 (en) | 2013-10-17 | 2020-09-24 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| PL3105317T3 (pl) | 2014-02-14 | 2019-02-28 | Cellectis | Komórki do immunoterapii zaprojektowane do celowania antygenu obecnego zarówno na komórkach odpornościowych, jak i komórkach patologicznych |
| ES2978312T3 (es) * | 2014-03-11 | 2024-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| ES2821149T3 (es) * | 2014-03-12 | 2021-04-23 | Prec Biosciences Inc | Eliminación del exón del gen de la distrofina mediante nucleasas modificadas genéticamente |
| US10494422B2 (en) | 2014-04-29 | 2019-12-03 | Seattle Children's Hospital | CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodies |
| LT3152312T (lt) | 2014-06-06 | 2020-04-27 | Regeneron Pharmaceuticals, Inc. | Tikslinio lokuso modifikavimo būdai ir kompozicijos |
| JP2017529841A (ja) | 2014-09-19 | 2017-10-12 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | キメラ抗原受容体 |
| CN107206024B (zh) | 2014-10-31 | 2021-12-03 | 宾夕法尼亚大学董事会 | 改变cart细胞中的基因表达及其用途 |
| EP4269601A3 (en) | 2015-03-27 | 2024-01-10 | President and Fellows of Harvard College | Modified t cells and methods of making and using the same |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| US10166255B2 (en) | 2015-07-31 | 2019-01-01 | Regents Of The University Of Minnesota | Intracellular genomic transplant and methods of therapy |
| CA3001008A1 (en) * | 2015-10-05 | 2017-04-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
| ES2920525T3 (es) | 2015-10-05 | 2022-08-05 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| CA3009637A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US20190241910A1 (en) | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| AU2017250769B2 (en) | 2016-04-15 | 2022-07-14 | Memorial Sloan Kettering Cancer Center | Transgenic T cell and chimeric antigen receptor T cell compositions and related methods |
| CA3068465A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| CA3095795A1 (en) | 2018-04-12 | 2019-10-17 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human t cell receptor alpha constant region gene |
-
2016
- 2016-10-05 CA CA3001008A patent/CA3001008A1/en active Pending
- 2016-10-05 DK DK19212310.7T patent/DK3680329T3/da active
- 2016-10-05 US US15/766,290 patent/US10799535B2/en active Active
- 2016-10-05 DK DK16785045.2T patent/DK3359660T3/da active
- 2016-10-05 JP JP2018517357A patent/JP6929837B2/ja active Active
- 2016-10-05 WO PCT/US2016/055472 patent/WO2017062439A1/en not_active Ceased
- 2016-10-05 EP EP21177206.6A patent/EP3940070A1/en active Pending
- 2016-10-05 EP EP16785045.2A patent/EP3359660B1/en active Active
- 2016-10-05 AU AU2016333886A patent/AU2016333886B2/en active Active
- 2016-10-05 ES ES19212310T patent/ES2883116T3/es active Active
- 2016-10-05 ES ES16785045T patent/ES2768984T3/es active Active
- 2016-10-05 EP EP19212310.7A patent/EP3680329B1/en active Active
-
2020
- 2020-09-09 US US17/016,056 patent/US11266693B2/en active Active
- 2020-12-15 AU AU2020289750A patent/AU2020289750B2/en active Active
-
2021
- 2021-08-11 JP JP2021131109A patent/JP2022000019A/ja active Pending
-
2022
- 2022-01-31 US US17/589,594 patent/US20220152112A1/en not_active Abandoned
-
2023
- 2023-04-03 AU AU2023202022A patent/AU2023202022A1/en not_active Abandoned
- 2023-08-18 JP JP2023133416A patent/JP2023175698A/ja active Pending
-
2024
- 2024-08-02 US US18/793,199 patent/US20240382526A1/en active Pending
-
2025
- 2025-06-03 JP JP2025092415A patent/JP2025143265A/ja active Pending
- 2025-11-24 AU AU2025271174A patent/AU2025271174A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018536390A5 (cg-RX-API-DMAC7.html) | ||
| JP2018535663A5 (cg-RX-API-DMAC7.html) | ||
| US11268065B2 (en) | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene | |
| US20220152112A1 (en) | Nucleic acids encoding engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene | |
| CA3151690A1 (en) | Genetically-edited immune cells and methods of therapy | |
| KR20220016475A (ko) | 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법 | |
| CN110139675A (zh) | 用具有工程化稳定的内源性foxp3基因表达的cd4 t细胞治疗自身免疫疾病的方法 | |
| KR20230157387A (ko) | Cas 효소를 이용한 다중 편집 | |
| HK40087901A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| CN117043327A (zh) | 用cas酶进行多重编辑 | |
| HK40043947A (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK40043947B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK1259673A1 (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene | |
| HK1259673B (en) | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |